Bio-Path Holdings (BPTH)
OTHER OTC:BPTH
Want to see BPTH full AI Analyst Report?
BPTH Stock Chart & Stats
$0.05
-$0.06(-5.61%)
At close: 4:00 PM EST
$0.05
-$0.06(-5.61%)
Day’s Range― - ―
52-Week Range$0.01 - $0.23
Previous CloseN/A
Volume216.71K
Average Volume (3M)24.92K
Market Cap
$1.89M
Enterprise Value$779.26K
Total Cash (Recent Filing)$12.00K
Total Debt (Recent Filing)$511.00K
Price to Earnings (P/E)―
Beta-0.60
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding50,297,450
10 Day Avg. Volume24,655
30 Day Avg. Volume24,916
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.46
Enterprise Value/Ebitda-0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Liposomal Delivery Platform (DNAbilize)A proprietary liposomal delivery technology addresses a core, durable barrier for RNAi therapeutics: safe, targeted intracellular delivery. This platform can materially increase clinical success probabilities, enable multiple programs, and support licensing or partnerships that persist beyond short-term market cycles.
Focused Hematologic Oncology Pipeline (AML)Concentrated focus on hematologic malignancies and defined assets (prexigebersen, BP1002) creates strategic clarity and potentially faster development pathways. Hematologic indications often allow smaller, faster trials and clearer regulatory endpoints, supporting durable value creation if clinical efficacy is demonstrated.
Low Absolute Debt BurdenVery low nominal debt reduces near-term interest and refinancing risk, preserving the option to focus capital on R&D. This structural funding flexibility lessens immediate solvency pressure even if equity financing is required, extending strategic choices over the medium term.
Bears Say
Negative Stockholders' Equity And Collapsing AssetsNegative equity and severe asset depletion materially weaken balance-sheet resilience. This impairs ability to obtain non-dilutive financing, increases counterparty and investor risk perception, and makes the company highly dependent on dilutive equity raises or partnerships to sustain operations over the coming months.
No Revenue; Persistent Operating LossesWith no commercial revenue and recurring large net losses, the company lacks internal funding from operations. Long-term viability thus hinges on successful clinical outcomes or external funding; absent clinical success, sustained losses increase the risk of program cutbacks or cessation.
Ongoing Cash Burn And Dependence On External FinancingRepeated negative operating and free cash flow forces reliance on capital markets or partners. Even with a reduced 2025 burn, recurring financings are likely, causing dilution and constraining long-term planning and investment in pivotal trials until sustainable cash generation is established.
Bio-Path Holdings News
BPTH FAQ
What was Bio-Path Holdings’s price range in the past 12 months?
Bio-Path Holdings lowest stock price was $0.01 and its highest was $0.23 in the past 12 months.
What is Bio-Path Holdings’s market cap?
Bio-Path Holdings’s market cap is $1.89M.
When is Bio-Path Holdings’s upcoming earnings report date?
Bio-Path Holdings’s upcoming earnings report date is Aug 18, 2026 which is in 74 days.
How were Bio-Path Holdings’s earnings last quarter?
Bio-Path Holdings released its earnings results on May 08, 2026. The company reported -$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.029.
Is Bio-Path Holdings overvalued?
According to Wall Street analysts Bio-Path Holdings’s price is currently Overvalued.
Does Bio-Path Holdings pay dividends?
Bio-Path Holdings does not currently pay dividends.
What is Bio-Path Holdings’s EPS estimate?
Bio-Path Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Path Holdings have?
Bio-Path Holdings has 50,297,450 shares outstanding.
What happened to Bio-Path Holdings’s price movement after its last earnings report?
Bio-Path Holdings reported an EPS of -$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Bio-Path Holdings?
Currently, no hedge funds are holding shares in BPTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio-Path Holdings
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.50% Other Institutional Investors
99.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---